Autolus Therapeutics Plc (AUTL) - News Archive

Autolus Therapeutics has recently announced the FDA approval of AUCATZYL (obecabtagene autoleucel or obe-cel) for the treatment of adults suffering from relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-...

The Future of CAR T-Cell Therapy: Autolus Therapeutics Showcases Promising Data at the 2024 ASH Annual Meeting Autolus Therapeutics, a pioneering organization in the realm of next-generation T-cell therapies, continues...

Clinical and Financial Update on Autolus Therapeutics at the 2024 SOHO Annual MeetingAutolus Therapeutics Plc, a clinical-stage biopharmaceutical company dedicated to the development of next-generation programmed T cell...

In the realm of cancer therapeutics, Autolus Therapeutics has recently presented intriguing new data from their Pivotal Phase 2 FELIX study of obe-cel (formerly known as AUTO1) for adult patients with relapsed or refrac...

The recent advances in B-ALL research were vividly highlighted at the American Society of Clinical Oncology (ASCO), where a Pivotal Phase 2 FELIX study s longer-term follow-up and additional data analysis for obe-cel we...

Autolus Therapeutics, a leading clinical-stage biopharmaceutical company specializing in the development of innovative immunotherapies for cancer treatment, has successfully obtained the prestigious certification from t...

BioNTech and Autolus Join Forces to Propel CAR-T Cell Therapy to New Frontiers in Cancer TreatmentIn a groundbreaking move, leading biotechnology companies BioNTech and Autolus have announced a strategic collaboration a...

The recently concluded American Society of Hematology (ASH) Annual Meeting for the year 2023 served as an important platform for Autolus Therapeutics to showcase their latest clinical data updates. This renowned biophar...